Literature DB >> 23046435

Changes of inflammatory factors after intravitreal triamcinolone acetonide for macular edema with central retinal vein occlusion.

Hidetaka Noma1, Hideharu Funatsu, Tatsuya Mimura.   

Abstract

PURPOSE: To investigate the effect of intravitreal triamcinolone acetonide (TA) on aqueous humor levels of vascular endothelial growth factor (VEGF), soluble intercellular adhesion molecule 1 (sICAM-1), and pigment epithelium-derived factor (PEDF) in patients with central retinal vein occlusion (CRVO) and macular edema.
METHODS: We measured VEGF, sICAM-1, and PEDF levels in aqueous humor samples from 2 eyes of 2 CRVO patients during injection of TA.
RESULTS: In both patients, the VEGF and sICAM-1 levels in aqueous humor samples obtained during initial injection of TA were higher than at the time of reinjection. Conversely, the initial PEDF levels were lower than those at reinjection.
CONCLUSIONS: Aqueous humor levels of VEGF and sICAM-1 were decreased by TA treatment in 2 CRVO patients, while PEDF was increased. Intravitreal TA could be an option for CRVO patients with a low PEDF level and/or moderate VEGF and sICAM-1 levels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23046435     DOI: 10.1089/jop.2011.0222

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  2 in total

Review 1.  A Review of Intraocular Biomolecules in Retinal Vein Occlusion: Toward Potential Biomarkers for Companion Diagnostics.

Authors:  Bingjie Wang; Xiao Zhang; Huan Chen; Adrian Koh; Chan Zhao; Youxin Chen
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

2.  The effect of antivascular endothelial growth factor therapy on the development of neovascular glaucoma after central retinal vein occlusion: a retrospective analysis.

Authors:  Christina L Ryu; Adrian Elfersy; Uday Desai; Thomas Hessburg; Paul Edwards; Hua Gao
Journal:  J Ophthalmol       Date:  2014-04-01       Impact factor: 1.909

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.